open access

Vol 61, No 5 (2010)
Original papers
Published online: 2010-11-04
Submitted: 2013-02-15
Get Citation

Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal

Agata Bałdys-Waligórska, Filip Gołkowski, Anna Krzentowska-Korek, Alicja Hubalewska-Dydejczyk
Endokrynologia Polska 2010;61(5):474-479.

open access

Vol 61, No 5 (2010)
Original papers
Published online: 2010-11-04
Submitted: 2013-02-15

Abstract


Introduction: A group of differentiated thyroid carcinoma (DTC) patients receiving post thyroidectomy rhTSH-aided radioiodine treatment (group I) was compared with patients treated with 131I following endogenous stimulation of TSH (group II) after L-thyroxine withdrawal.
Material and methods: Group I consisted of 66 patients of mean age 51.7 ± 16.2 years (58 females and 8 males). Group II included 76 patients of mean age 54.8 ± 14.7 years (67 females and 9 males). All patients underwent total thyroidectomy and central lymph node dissection and additionally lateral lymph node excision, if required. Prior to radioiodine treatment thyroid volume (VT) and 24-hour 131I uptake were evaluated. TSH and Tg concentrations were measured prior to and after endogenous and exogenous stimulation of TSH. Whole-body post-therapeutic scintigraphy was evaluated. Basic statistics, W Shapiro-Wilk, Wilcoxon, and U Mann-Whitney tests were applied.
Results: Median values of VT and of 24-hr 131I uptake in groups I and II were not significantly different. The differences between median values of serum TSH concentration after stimulation in groups I and II were statistically significant (p < 0.05), respective medians being 100.0 &#956;U/mL (IQR = 107.3) and 78.8 &#956;U/mL (IQR = 47.7). Median values of serum Tg concentrations in groups I and II following TSH stimulation prior to radioiodine treatment were 2.6 ng/ml (IQR = 8.4) and 4.9 ng/mL (IQR = 12.6), respectively, the difference not being statistically significant. Following rhTSH treatment no adverse effects were observed compared to LT4 withdrawal.
Conclusions: rhTSH may be safely used for 131I thyroid remnant ablation in low-risk DTC patients.
(Pol J Endocrinol 2010; 61 (5): 474-479)

Abstract


Introduction: A group of differentiated thyroid carcinoma (DTC) patients receiving post thyroidectomy rhTSH-aided radioiodine treatment (group I) was compared with patients treated with 131I following endogenous stimulation of TSH (group II) after L-thyroxine withdrawal.
Material and methods: Group I consisted of 66 patients of mean age 51.7 &#177; 16.2 years (58 females and 8 males). Group II included 76 patients of mean age 54.8 &#177; 14.7 years (67 females and 9 males). All patients underwent total thyroidectomy and central lymph node dissection and additionally lateral lymph node excision, if required. Prior to radioiodine treatment thyroid volume (VT) and 24-hour 131I uptake were evaluated. TSH and Tg concentrations were measured prior to and after endogenous and exogenous stimulation of TSH. Whole-body post-therapeutic scintigraphy was evaluated. Basic statistics, W Shapiro-Wilk, Wilcoxon, and U Mann-Whitney tests were applied.
Results: Median values of VT and of 24-hr 131I uptake in groups I and II were not significantly different. The differences between median values of serum TSH concentration after stimulation in groups I and II were statistically significant (p < 0.05), respective medians being 100.0 &#956;U/mL (IQR = 107.3) and 78.8 &#956;U/mL (IQR = 47.7). Median values of serum Tg concentrations in groups I and II following TSH stimulation prior to radioiodine treatment were 2.6 ng/ml (IQR = 8.4) and 4.9 ng/mL (IQR = 12.6), respectively, the difference not being statistically significant. Following rhTSH treatment no adverse effects were observed compared to LT4 withdrawal.
Conclusions: rhTSH may be safely used for 131I thyroid remnant ablation in low-risk DTC patients.
(Pol J Endocrinol 2010; 61 (5): 474-479)
Get Citation

Keywords

differentiated thyroid carcinoma; radioiodine treatment; rhTSH

About this article
Title

Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal

Journal

Endokrynologia Polska

Issue

Vol 61, No 5 (2010)

Pages

474-479

Published online

2010-11-04

Bibliographic record

Endokrynologia Polska 2010;61(5):474-479.

Keywords

differentiated thyroid carcinoma
radioiodine treatment
rhTSH

Authors

Agata Bałdys-Waligórska
Filip Gołkowski
Anna Krzentowska-Korek
Alicja Hubalewska-Dydejczyk

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl